©2024 Stanford Medicine
Treatment Trial for Psychogenic Nonepileptic Seizures
Recruiting
I'm InterestedTrial ID: NCT00835627
Purpose
The investigators propose that patients who receive targeted pharmacotherapy (sertraline) or
focused psychotherapy (cognitive behavioral therapy-informed psychotherapy (CBT-ip) for NES)
or combined treatment (CBT-ip + sertraline) will report fewer nonepileptic seizures (NES)
compared to patients who receive community care / treatment as usual (TAU). The purpose of
this study is to provide pilot testing and data to inform the future multicenter randomized
controlled trial based on the hypothesis.
Official Title
Medication and Psychotherapy Treatment Trial for Psychogenic Nonepileptic Seizures
Stanford Investigator(s)
Charles DeBattista
Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology - Adult)
Eligibility
Inclusion Criteria:
- Video electroencephalogram (EEG) confirmed diagnosis of NES
- Have at least one nonepileptic seizure per month
- Able to complete self report symptom scales
- Not receiving optimized sertraline
Exclusion Criteria:
- Equivocal EEG findings
- using monoamine oxidase inhibitors (MAOIs), pimozide, or sumatriptan
- allergy/sensitivity to sertraline
- current alcohol/drug dependence
- serious medical illness requiring current hospitalization
Intervention(s):
other: Standard Care
drug: Sertraline
behavioral: CBT-ip
other: Combined (sertraline + CBT-ip)
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jessica Hawkins
6507238323